Biased Ligands. Better Drugs.

Press Releases

4/8/15 - Trevena CEO to present at the 14th Annual Needham Healthcare Conference

Trevena, Inc. (NASDAQ: TRVN), today announced Maxine Gowen, Ph.D., its chief executive officer, will present a company overview at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 10:00 a.m. EDT in New York. Read More

3/18/15 - Trevena Reports Full Year 2014 Financial Results
Trevena, Inc. (NASDAQ: TRVN), today announced financial results for the fourth quarter and year ended December 31, 2014. Read More

3/18/15 - Trevena CMO to Present at the BioCentury 22nd Annual Future Leaders in the Biotech Industry conference
Trevena, Inc. (NASDAQ: TRVN), today announced David Soergel, M.D., its chief medical officer, will present a company overview at the BioCentury 22nd Annual Future Leaders in the Biotech Industry conference on Friday March 20, 2015 at 3:00 p.m. EDT in New York. Read More

3/11/15 - Trevena to Host Conference Call on March 18th to Discuss Full Year 2014 Financial Results
Trevena, Inc. (NASDAQ: TRVN), today announced that it will host a conference call on Wednesday, March 18, 2015 at 8:30 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2014. Read More

3/9/15 - Trevena completes interim analysis and announces plans for ongoing Phase 2b BLAST-AHF trial of TRV027 in acute heart failure
Trevena, Inc. (NASDAQ: TRVN), today announced its plans for the continuation of the BLAST-AHF trial – a double-blind placebo-controlled study of TRV027 in patients with acute heart failure (AHF) – following the recent completion of the pre-specified interim analysis. Read More

2/9/15 - Trevena Announces Positive Results from Phase 1 Multiple Ascending Dose Study of TRV734 for Moderate to Severe Acute and Chronic Pain
Trevena, Inc. (NASDAQ: TRVN), today announced positive data from a Phase 1 multiple ascending dose study of TRV734, a novel drug candidate in development as an orally administered treatment for moderate-to-severe acute and chronic pain. Read More

2/3/15 - Trevena CEO to Present at the 17th Annual BIO CEO & Investor Conference
Trevena, Inc. (NASDAQ: TRVN), today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present a company overview at the 17th Annual BIO CEO & Investor Conference on Tuesday February 10, 2015 at 8:00 a.m. EST in New York City. Read More

2/3/15 - TRV027 Phase 2b BLAST-AHF Trial Design Published in Journal of the American College of Cardiology: Heart Failure
Trevena, Inc., today announced publication of the trial design for its ongoing Phase 2b study of TRV027 in acute heart failure (AHF) in the Journal of the American College of Cardiology: Heart Failure. Read More

1/6/15 - Trevena Initiates Second Phase 2b Study of TRV130 for Acute Postoperative Pain
Trevena, Inc., today announced the initiation of a Phase 2b clinical trial of TRV130 for acute postoperative pain in patients following abdominoplasty surgery. Read More

12/17/14 - Trevena Appoints Anne M. Phillips to the Board of Directors
Trevena, Inc. (NASDAQ: TRVN), today announced that Anne M. Phillips, M.D. has been appointed to Trevena’s Board of Directors. Dr. Phillips replaces Farah Champsi, managing director at Alta Partners, who is stepping down from the Board following the Company’s initial public offering earlier this year. Read More

12/10/14 - Trevena Announces Closing of Public Offering and Partial Exercise of Underwriters’ Option to Purchase Additional Shares
Trevena, Inc. today announced the closing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of $4.00 per share. Read More

12/4/14 - Trevena Announces Pricing of Public Offering
Trevena, Inc. (NASDAQ: TRVN), today announced the pricing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of $4.00 per share. Read More

12/1/14 - Trevena Announces Commencement of Public Offering
Trevena, Inc. (NASDAQ: TRVN), today announced that it intends to offer and sell $40.0 million of shares of its common stock in an underwritten public offering. Read More

11/17/14 - Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain
Trevena, Inc. (NASDAQ: TRVN), today announced positive top-line data from its randomized, double-blind, placebo- and active-controlled Phase 2a/b trial of TRV130 in moderate-to-severe postoperative acute pain. Read More

11/11/14 - Trevena Reports Third Quarter 2014 Financial Results and Provides a Corporate Update
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced financial results for the quarter ended September 30, 2014 and provided an update regarding its ongoing clinical programs. Read More

News Archive

Copyright © Trevena, Inc.